Clarus Therapeutics (OTCMKTS:CRXTQ – Get Rating) and Innate Pharma (OTCMKTS:IPHYF – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.
Insider and Institutional Ownership
0.3% of Clarus Therapeutics shares are owned by institutional investors. 5.3% of Clarus Therapeutics shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Clarus Therapeutics and Innate Pharma’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clarus Therapeutics | $13.96 million | 0.00 | -$40.62 million | ($1.30) | 0.00 |
| Innate Pharma | $60.78 million | 4.41 | -$61.22 million | N/A | N/A |
Profitability
This table compares Clarus Therapeutics and Innate Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clarus Therapeutics | N/A | N/A | N/A |
| Innate Pharma | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of current ratings and price targets for Clarus Therapeutics and Innate Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clarus Therapeutics | 0 | 2 | 0 | 0 | 2.00 |
| Innate Pharma | 0 | 0 | 1 | 0 | 3.00 |
Volatility & Risk
Clarus Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Summary
Innate Pharma beats Clarus Therapeutics on 5 of the 8 factors compared between the two stocks.
About Clarus Therapeutics
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
About Innate Pharma
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
